Cisplatin and Radiation Therapy in Treating Patients With Stage IV Cancer of the Head and Neck
Public ClinicalTrials.gov record NCT00002932. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Multi-Institutional Trial of Targeted Supradose Cisplatin Chemoradiation for Stage IV Squamous Cell Carcinoma of the Head and Neck
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of cisplatin and radiation therapy in treating patients with stage IV cancer of the head and neck.
Study identification
- NCT ID
- NCT00002932
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 1997 (Type not available)
- Primary completion
- Mar 2001 (Actual)
- Completion
- Mar 2005 (Actual)
- Last update posted
- Nov 21, 2014
1997 – 2005
United States locations
- U.S. sites
- 13
- U.S. states
- 8
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Diego Cancer Center | La Jolla | California | 92093-0658 | — |
| UCSF Cancer Center and Cancer Research Institute | San Francisco | California | 94115-0128 | — |
| University of Iowa Hospitals and Clinics | Iowa City | Iowa | 52242 | — |
| MBCCOP - LSU Medical Center | New Orleans | Louisiana | 70112 | — |
| Marlene & Stewart Greenebaum Cancer Center, University of Maryland | Baltimore | Maryland | 21201 | — |
| CCOP - Baptist Cancer Institute | Memphis | Tennessee | 38117 | — |
| University of Tennessee, Memphis Cancer Center | Memphis | Tennessee | 38163 | — |
| Vanderbilt Cancer Center | Nashville | Tennessee | 37232-6838 | — |
| Fletcher-Allen Health Care | Burlington | Vermont | 05401 | — |
| Green Mountain Oncology Group | Rutland | Vermont | 05701 | — |
| Naval Medical Center, Portsmouth | Portsmouth | Virginia | 23708-2197 | — |
| University Cancer Center | Seattle | Washington | 98195 | — |
| University of Washington Neutron Facility and Cancer Center | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00002932, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 21, 2014 · Synced Oct 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00002932 live on ClinicalTrials.gov.